RU2736752C2 - Метадихол - жидкие и гелевые нанолекарственные препараты - Google Patents

Метадихол - жидкие и гелевые нанолекарственные препараты Download PDF

Info

Publication number
RU2736752C2
RU2736752C2 RU2017116682A RU2017116682A RU2736752C2 RU 2736752 C2 RU2736752 C2 RU 2736752C2 RU 2017116682 A RU2017116682 A RU 2017116682A RU 2017116682 A RU2017116682 A RU 2017116682A RU 2736752 C2 RU2736752 C2 RU 2736752C2
Authority
RU
Russia
Prior art keywords
disease
levels
patients
thyroid
treatment
Prior art date
Application number
RU2017116682A
Other languages
English (en)
Russian (ru)
Other versions
RU2017116682A3 (enExample
RU2017116682A (ru
Inventor
Палаякотай Р. РАГХАВАН
Original Assignee
Наноркс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Наноркс, Инк. filed Critical Наноркс, Инк.
Publication of RU2017116682A publication Critical patent/RU2017116682A/ru
Publication of RU2017116682A3 publication Critical patent/RU2017116682A3/ru
Application granted granted Critical
Publication of RU2736752C2 publication Critical patent/RU2736752C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
RU2017116682A 2013-03-15 2014-03-11 Метадихол - жидкие и гелевые нанолекарственные препараты RU2736752C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794490P 2013-03-15 2013-03-15
US61/794,490 2013-03-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015143270A Division RU2631600C2 (ru) 2013-03-15 2014-03-11 Метадихол® - жидкие и гелевые нанолекарственные препараты

Publications (3)

Publication Number Publication Date
RU2017116682A RU2017116682A (ru) 2018-10-23
RU2017116682A3 RU2017116682A3 (enExample) 2020-06-03
RU2736752C2 true RU2736752C2 (ru) 2020-11-19

Family

ID=51530033

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017116682A RU2736752C2 (ru) 2013-03-15 2014-03-11 Метадихол - жидкие и гелевые нанолекарственные препараты
RU2015143270A RU2631600C2 (ru) 2013-03-15 2014-03-11 Метадихол® - жидкие и гелевые нанолекарственные препараты

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015143270A RU2631600C2 (ru) 2013-03-15 2014-03-11 Метадихол® - жидкие и гелевые нанолекарственные препараты

Country Status (15)

Country Link
US (1) US9006292B2 (enExample)
EP (1) EP2968209B1 (enExample)
JP (2) JP5996146B2 (enExample)
KR (1) KR101700949B1 (enExample)
CN (1) CN105188687B (enExample)
AU (1) AU2014235779B2 (enExample)
BR (1) BR112015011379B1 (enExample)
CA (1) CA2894370C (enExample)
DK (1) DK2968209T3 (enExample)
HK (1) HK1212247A1 (enExample)
MX (1) MX359686B (enExample)
RU (2) RU2736752C2 (enExample)
SG (1) SG11201506430XA (enExample)
WO (1) WO2014150609A1 (enExample)
ZA (1) ZA201505436B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
AU2020358364B2 (en) * 2019-09-30 2025-10-09 Tolmar International Limited Liquid polymer compositions and systems for extended delivery of peptides as active pharmaceutical ingredients
US11554087B2 (en) 2020-11-05 2023-01-17 The Gillette Company Llc Shaving aid comprising an antioxidant
CN114699537B (zh) * 2022-03-07 2024-06-21 西安交通大学医学院第一附属医院 一种改善缺氧增敏pd-1抗体疗效的ros响应抗癌药物
EP4618972A1 (en) * 2022-11-18 2025-09-24 Phytoceutical Limited Biofilm treatment
CN118011012B (zh) * 2024-02-19 2025-01-21 中国科学院昆明动物研究所 LL-37-ApoB-100生物标志物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670471A (en) * 1981-11-03 1987-06-02 Clark Lealand L Treatment for inflammatory skin disease
RU2361430C2 (ru) * 2003-06-27 2009-07-20 Индена С.П.А. Диетическая композиция, содержащая вазопротекторные агенты
US20100215752A1 (en) * 2009-02-23 2010-08-26 NanoRx, Inc. Policosanol nanoparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191288A1 (en) 1996-02-12 2009-07-30 Squires Meryl J Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
US20030198616A1 (en) * 2002-04-23 2003-10-23 Combe Incorporated Moisturizing skin gel and method
EP1511467A1 (en) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
US7217546B1 (en) * 2003-07-01 2007-05-15 Sami Labs Ltd Commercially viable process for high purity of fatty alcohol C24 to C36 and its cosmetic application for skin hair and nails
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
JP2010511723A (ja) * 2006-12-04 2010-04-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 局所医薬組成物
AU2010302350B2 (en) * 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
CA2844073C (en) * 2010-08-23 2015-10-13 NanoRx, Inc. Policosanol nanoparticles
US20130045179A1 (en) * 2011-08-15 2013-02-21 Mihai Ciustea Combination therapy and methods for treatment and prevention of hyperproliferative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670471A (en) * 1981-11-03 1987-06-02 Clark Lealand L Treatment for inflammatory skin disease
RU2361430C2 (ru) * 2003-06-27 2009-07-20 Индена С.П.А. Диетическая композиция, содержащая вазопротекторные агенты
US20100215752A1 (en) * 2009-02-23 2010-08-26 NanoRx, Inc. Policosanol nanoparticles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CABRERA L. et al. tudy of the interection between policosanol and excipients". Boll. Chem Farm 2002;141(2):138-42. *

Also Published As

Publication number Publication date
RU2015143270A (ru) 2017-04-27
BR112015011379B1 (pt) 2022-10-11
BR112015011379A2 (enExample) 2017-08-22
JP5996146B2 (ja) 2016-09-21
US9006292B2 (en) 2015-04-14
KR20150127575A (ko) 2015-11-17
KR101700949B1 (ko) 2017-01-31
CN105188687A (zh) 2015-12-23
RU2017116682A3 (enExample) 2020-06-03
ZA201505436B (en) 2016-07-27
MX359686B (es) 2018-10-05
RU2631600C2 (ru) 2017-09-25
AU2014235779B2 (en) 2015-11-26
MX2015008676A (es) 2016-04-25
SG11201506430XA (en) 2015-09-29
RU2017116682A (ru) 2018-10-23
JP2016512827A (ja) 2016-05-09
AU2014235779A1 (en) 2015-09-03
DK2968209T3 (da) 2021-01-04
CA2894370A1 (en) 2014-09-25
US20140275285A1 (en) 2014-09-18
EP2968209A4 (en) 2016-11-02
EP2968209A1 (en) 2016-01-20
CN105188687B (zh) 2018-05-01
JP6346918B2 (ja) 2018-06-20
HK1212247A1 (en) 2016-06-10
CA2894370C (en) 2016-01-12
EP2968209B1 (en) 2020-12-16
WO2014150609A1 (en) 2014-09-25
JP2017008057A (ja) 2017-01-12

Similar Documents

Publication Publication Date Title
RU2736752C2 (ru) Метадихол - жидкие и гелевые нанолекарственные препараты
Lee et al. Impaired wound healing and angiogenesis in eNOS-deficient mice
McNatty et al. The effects of immunizing sheep with different BMP15 or GDF9 peptide sequences on ovarian follicular activity and ovulation rate
Noonin et al. Systematic analysis of modulating activities of native human urinary Tamm-Horsfall protein on calcium oxalate crystallization, growth, aggregation, crystal-cell adhesion and invasion through extracellular matrix
Dowdall et al. Inhibition of high-affinity choline transport in peripheral cholinergic endings by presynaptic snake venom neurotoxins
Svensson et al. Vitamin D-induced up-regulation of human keratinocyte cathelicidin anti-microbial peptide expression involves retinoid X receptor α
WO2025054501A1 (en) Modified silk fibroin and medical uses thereof
Lu et al. Exosomes derived from umbilical cord mesenchymal stem cells promote healing of complex perianal fistulas in rats
Nardi “Essential” and “nonessential” amino acids in the urine of severely burned patients
Gharat et al. In-vitro and in-vivo evaluation of the developed curcumin-cyclosporine-loaded nanoemulgel for the management of rheumatoid arthritis
Gao et al. Insufficient iron improves pristane-induced lupus by promoting treg cell expansion
Majewski et al. Olive leaf‐derived PPAR agonist complex induces collagen IV synthesis in human skin models
Fu et al. OX40L blockade cellular nanovesicles for autoimmune diseases therapy
Tan et al. Oral vitamin A and retinoic acid supplementation stimulates antibody production and splenic Stra6 expression in tetanus toxoid–immunized mice
Wang et al. Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration
Elnagar et al. Policosanol ameliorates renal inflammation and pyroptosis in hypercholesterolemic rabbits via modulation of HMGB1/PI3K/mTOR/NLRP3/Caspase-1 pathway
Liu et al. Regulation of sheep α-TTP by dietary vitamin E and preparation of monoclonal antibody for sheep α-TTP
Yang et al. Osteopontin and integrin are involved in cholesterol gallstone formation
CA3026620C (en) Formulation for use in the treatment of uremic pruritus
Gates et al. Human neonatal keratinocytes have very high levels of cellular vitamin A-binding proteins
DUNCAN et al. A 1, 25-dihydroxyvitamin D3 receptor-like protein in mammalian and avian liver nuclei
Kamanna et al. Low density lipoproteins transactivate EGF receptor: role in mesangial cell proliferation
Xie et al. NG@ B87@ HA Hydrogel regulates glycolysis bidirectionally to promote wound healing in type 2 diabetes mellitus
Juncos et al. Renal tubular acidosis and vasculitis associated with IgE deposits in the kidney and small vessels
Du et al. Chromobox protein homolog 7 (CBX7) deficiency inhibits osteoblast ferroptosis by activating the Nrf2 function in type 2 diabetic osteoporosis